Structured evidence table for Green Tea Cardiometabolic Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Green Tea Cardiometabolic Meta-Analysis | This systematic review and meta-analysis aimed to synthesize observational evidence on tea consumption and hypertension and to explore whether this association differed according to tea type, sex, age, region, and hypertension diagnostic threshold. | 1 | Jiang R (2026) | The association between tea consumption and hypertension: a systematic review and meta-analysis. |
| Green Tea Cardiometabolic Meta-Analysis | In 16 cross-sectional studies, tea consumption was weakly associated with lower hypertension prevalence ( OR = 0.92, 95% CI : 0.87-0.97, I 2 = 62.8%). | 1 | Jiang R (2026) | The association between tea consumption and hypertension: a systematic review and meta-analysis. |
| Green Tea Cardiometabolic Meta-Analysis | This inverse association was stronger for black tea drinkers, Asians, women, participants aged ORs of the four cohort studies indicated a 13% lower hypertension risk ( OR = 0.87, 95% CI : 0.84-0.92, I 2 = 31.9%). | 1 | Jiang R (2026) | The association between tea consumption and hypertension: a systematic review and meta-analysis. |
| Green Tea Cardiometabolic Meta-Analysis | Objective The association between habitual tea consumption and hypertension remains controversial. | 1 | Jiang R (2026) | The association between tea consumption and hypertension: a systematic review and meta-analysis. |
| Green Tea Cardiometabolic Meta-Analysis | Experimental studies provide substantial biological plausibility, while epidemiological studies have frequently associated habitual tea consumption with favorable cardiovascular outcomes. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Cardiometabolic Meta-Analysis | However, these findings arise from heterogeneous evidence streams—including preclinical experiments, trials of surrogate risk markers, observational cohorts, and genetic analyses—and therefore differ substantially in their ability to support causal inference. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Cardiometabolic Meta-Analysis | Such heterogeneity provides a rationale for exploring individualized tea-consumption strategies, but current evidence is insufficient to support disease-specific tea selection or therapeutic dosing. | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
| Green Tea Cardiometabolic Meta-Analysis | 1 2 Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide (). | 3 | Liu Rong (2026) | Tea consumption and cardiovascular risk and outcomes: mechanistic insights, epidemiological evidence, and clinical implications |
Source documents